Product image of Micofenolato De Mofetil Bluelife (Mycophenolate Mofetil) supplied by GNH India

Micofenolato De Mofetil Bluelife

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Micofenolato De Mofetil Bluelife (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Bluelife, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute rejection after organ transplantation and to treat certain autoimmune kidney disorders such as lupus nephritis.
GNH India supplies Micofenolato De Mofetil Bluelife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Axone, Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is used in the management of transplant‑related immune responses and selected autoimmune kidney disease.

  • Kidney transplantation: helps prevent acute graft rejection.
  • Heart transplantation: reduces the risk of early rejection episodes.
  • Lupus nephritis: aids in controlling renal inflammation and preserving kidney function.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanosine nucleotide synthesis, limiting the proliferation of T‑ and B‑lymphocytes that depend on the de novo pathway, thereby suppressing the immune response essential for graft rejection and autoimmune activity.

Side Effects

Mycophenolate Mofetil may cause a range of adverse reactions.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: frequent loose stools.
  • Vomiting: occasional episodes after dosing.
  • Abdominal pain: cramping or discomfort.
  • Headache: transient mild pain.
  • Infections: increased susceptibility to common viral or bacterial infections.

Serious or Rare Side Effects

  • Leukopenia: significant drop in white blood cells.
  • Anemia: reduced red blood cell count.
  • Severe infections: opportunistic or systemic infections.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Malignancy: increased risk of certain cancers with long‑term use.
  • Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust dose if creatinine clearance is impaired.
  • Avoid use in pregnancy: category D, discuss risks versus benefits with the patient.
  • Screen for infections: treat opportunistic infections promptly and avoid live vaccines.
  • Review concomitant medications: watch for additive bone‑marrow suppression.
  • Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Mycophenolate Mofetil can interact with several drugs, requiring careful management.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias.
  • Cyclosporine: increased mycophenolate exposure can heighten toxicity.
  • Antacids containing aluminum or magnesium: reduce oral absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely)

  • Rifampin: induces metabolism and may lower drug levels.
  • Warfarin: may increase INR and bleeding risk.
  • Live vaccines: reduced efficacy; consider timing or avoidance while on therapy.

Frequently Asked Questions

Micofenolato De Mofetil Bluelife contains mycophenolate mofetil, an immunosuppressive agent used to prevent acute rejection after kidney, heart or liver transplantation and to treat autoimmune kidney conditions such as lupus nephritis.

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks guanosine nucleotide synthesis, limiting the proliferation of T‑ and B‑lymphocytes and thereby dampening the immune response.

The dose is individualized by the prescribing clinician based on the specific transplant protocol, renal function, and patient tolerance. Dosage adjustments are made according to therapeutic monitoring and clinical response.

Mycophenolate mofetil is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless no safer alternative exists, and breastfeeding is not recommended because the drug is excreted in milk.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azathioprine, mycophenolate mofetil offers more selective inhibition of lymphocyte proliferation and often provides better graft‑survival rates. Unlike calcineurin inhibitors such as cyclosporine, it does not cause nephrotoxicity, but it may require more frequent blood‑count monitoring.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually twice daily, with or without food as directed by the prescriber. Swallow tablets whole with a full glass of water; do not crush or chew unless instructed.

Serious adverse events include severe leukopenia or neutropenia, anemia, opportunistic infections, liver toxicity, and rare conditions such as progressive multifocal leukoencephalopathy (PML). Prompt reporting of fever, unusual bruising, jaundice or neurological symptoms is essential.

Patients with known hypersensitivity to mycophenolate mofetil or any excipients, those who are pregnant, have uncontrolled severe infections, or have severe hepatic impairment should avoid this medication. Clinicians should also exercise caution in patients with pre‑existing bone‑marrow suppression.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT